CD163 and lung adenocarcinoma: In this work, the authors used a quantitative phosphor-integrated dot staining of the CSF-1R on CD68+ CD163+ TAMs in 195 lung adenocarcinoma cases and discovered that the presence of CSF-1R-expressing TAMs is associated with high mortality rates particularly in never-smoking patients, implying that CSF-1R-expressing TAMs might wield more potent tumor-promoting effects in never-smoking lung adenocarcinoma patients, making the CSF-1R a possible therapeutic target in this specific cohort of patients [64].